Showing results (11-20 of 24) with videos related to
Sort By:
Pageof 3
Journal for Immunotherapy of Cancer|November 2, 2021
BT7480, a novel fully synthetic Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™) induces tumor localized CD137 agonismKristen Hurov, Johanna Lahdenranta, Punit Upadhyaya, et al.Journal of Medicinal Chemistry|December 23, 2016
Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 InhibitorsScott D Cowen, Daniel Russell, Leslie A Dakin, et al.Journal for Immunotherapy of Cancer|January 27, 2021
Anticancer immunity induced by a synthetic tumor-targeted CD137 agonistPunit Upadhyaya, Johanna Lahdenranta, Kristen Hurov, et al.Molecular Cancer Therapeutics|September 16, 2022
BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid TumorsMichael Rigby, Gavin Bennett, Liuhong Chen, et al.Elife|May 17, 2016
ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen ReceptorZineb Mounir, Joshua M Korn, Thomas Westerling, et al.Nature Medicine|April 8, 2015
Studying clonal dynamics in response to cancer therapy using high-complexity barcodingHyo-eun C Bhang, David A Ruddy, Viveksagar Krishnamurthy Radhakrishna, et al.Cancer Discovery|June 5, 2016
CRISPR Screens Provide a Comprehensive Assessment of Cancer Vulnerabilities but Generate False-Positive Hits for Highly Amplified Genomic RegionsDiana M Munoz, Pamela J Cassiani, Li Li, et al.Proceedings of the National Academy of Sciences of the United States of America|February 13, 2014
Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancersGregory R Hoffman, Rami Rahal, Frank Buxton, et al.Cancer Research|January 19, 2018
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAFWenlin Shao, Yuji M Mishina, Yun Feng, et al.Cell Reports|November 1, 2018
TRPS1 Is a Lineage-Specific Transcriptional Dependency in Breast CancerRobert M Witwicki, Muhammad B Ekram, Xintao Qiu, et al.Pageof 3